Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rezolute, Inc. - Common Stock (NV) (NQ:RZLT)

2.165 -0.195 (-8.26%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rezolute, Inc. - Common Stock (NV)

< Previous 1 2 3 4 5 6 Next >
News headline image
Insiders Made Their Bets in 2025—These Were the Top 5 Stocks They Bought ↗
Insiders bought these stocks heavily in 2025, but investors should be wary; only some of them are good buys for 2026 portfolios. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rezolute, Inc. - RZLT
From Pomerantz LLP
Via GlobeNewswire
News headline image
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Which stocks are gapping on Wednesday? ↗
Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
REZOLUTE INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
On Wednesday, there are stocks with unusual volume. Let's take a look. ↗
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look. 
Via Chartmill
News headline image
Unusual volume stocks in Monday's session ↗
Let's have a look at what is happening on the US markets on Monday. Below you can find the stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
Unusual volume stocks in Friday's session ↗
Unusual volume stocks are being observed in Friday's session. 
Via Chartmill
News headline image
Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure
From Hagens Berman
Via Business Wire
News headline image
Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT
From DJS Law Group
Via Business Wire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
RZLT Stock Lost Nearly 90% Of Its Value Today – What Did The Company’s Latest Trial Reveal? ↗
Rezolute said that its Phase 3 sunRIZE trial of ersodetug to treat low blood pressure failed to meet its primary endpoint. 
Via Stocktwits
News headline image
Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute to Host Virtual Investor Event on Ersodetug Development Program
Webcast scheduled for Monday, November 10 at 12:00 pm EST 
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute to Participate in Upcoming Investor Conferences
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Rezolute, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Rezolute Inc (NASDAQ:RZLT) Reports Q4 FY2025 Results, Posts Wider-Than-Expected Loss Amid Strong Clinical Progress ↗
Rezolute Inc. reports Q4 FY2025 results, posting a net loss but maintaining a strong cash position of $167.9M to fund its Phase 3 clinical trials for congenital and tumor hyperinsulinism. 
Via Chartmill
News headline image
Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Stock: FDA Fast Track Fuels 2025 Breakout ↗
Rezolute, Inc. is on track for its lead candidate to hit blockbuster status, but there are still risks and hurdles to overcome. 
Via MarketBeat
News headline image
Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute to Participate in Upcoming Investor Conferences
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer
Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ersodetug 
From Rezolute, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.